Camber Capital Management LP Replimune Group, Inc. Transaction History

Camber Capital Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$5.01 - $9.46 $7.01 Million - $13.2 Million	-1,400,000 Reduced 50.91%	1,350,000 $12.2 Million
Q1 2024 May 15, 2024	BUY	$6.87 - $9.31 $12 Million - $16.3 Million	1,750,000 Added 175.0%	2,750,000 $22.5 Million
Q4 2023 Feb 14, 2024	SELL	$6.75 - $16.18 $6.75 Million - $16.2 Million	-1,000,000 Reduced 50.0%	1,000,000 $8.43 Million
Q3 2023 Nov 14, 2023	BUY	$15.96 - $22.18 $7.18 Million - $9.98 Million	450,000 Added 29.03%	2,000,000 $34.2 Million
Q2 2023 Aug 14, 2023	BUY	$15.65 - $24.1 $4.7 Million - $7.23 Million	300,000 Added 24.0%	1,550,000 $36 Million
Q1 2023 May 15, 2023	BUY	$17.48 - $29.09 $4.37 Million - $7.27 Million	250,000 Added 25.0%	1,250,000 $22.1 Million
Q4 2022 Feb 14, 2023	BUY	$17.09 - $27.91 $17.1 Million - $27.9 Million	1,000,000 New	1,000,000 $27.2 Million

149

68M

52.3K

80.3K

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $616M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

Get notified when there are updates to the investment portfolio of Camber Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Camber Capital Management LP with notifications on news.